UK markets closed

Cellectar Biosciences, Inc. (CLRB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.9850+0.3500 (+9.63%)
As of 03:54PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.6350
Open3.8400
Bid3.9400 x 900
Ask4.0300 x 300
Day's range3.7900 - 4.0700
52-week range1.3000 - 4.4500
Volume1,678,279
Avg. volume1,861,552
Market cap48.969M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-3.2600
Earnings date02 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.60
  • Insider Monkey

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript

    Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 Cellectar Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today’s call is being recorded. Before […]

  • Thomson Reuters StreetEvents

    Q4 2023 Cellectar Biosciences Inc Earnings Call

    Q4 2023 Cellectar Biosciences Inc Earnings Call

  • GlobeNewswire

    Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

    Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. “2023 was a year of significant progress for Cellectar, culminating in the January announceme